

Yondelis[®] recommended by the National Comprehensive Cancer Network to treat uterine leiomyosarcoma in clinical trials

- *The "National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology" on uterine neoplasms highly recommends the inclusion of patients in clinical trials with Yondelis[®] to treat uterine leiomyosarcoma.*
- *Leiomyosarcomas are aggressive tumours that are often difficult to treat.*
- *The NCCN is a not-for-profit alliance of 23 of the world's leading cancer centres devoted to research, and education and patient care.*

Madrid, 17 February 2014:The "National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology" on uterine neoplasms highly recommends the inclusion of patients with uterine leiomyosarcoma in clinical trials with Yondelis[®], which has proven to be effective (overall survival: 13.9 months) in patients for which standard lines of treatment have failed.

Uterine leiomyosarcoma is a soft tissue sarcoma (STS) which arises in the smooth muscle cells of the uterine wall. Soft tissue sarcomas are malignant tumours arising from mesenchymal cell lines. They comprise a heterogeneous group of cancers and account for 0.7% of malignancies. Broadly speaking, they are classified according to the normal cell line that they most closely resemble. Of all soft tissue sarcomas, approximately 5-10% are leiomyosarcomas. Leiomyosarcoma of soft tissue is thought to arise from the smooth muscle cells lining small blood vessels. They are aggressive tumours which are often difficult to treat.

The NCCN is a not-for-profit alliance of 23 of the world's leading cancer centres devoted to research, and education and patient care. Its main objectives are to improve the quality, effectiveness and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. NCCN

promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer.

About PharmaMar

PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. Yondelis® is currently approved for soft tissue sarcoma (STS) in 42 countries outside the EEA, and for platinum-sensitive relapsed ovarian cancer (ROC) in 31 of those countries plus Brazil. Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia's website: www.zeltia.com